Asia-Pacific Meglitinide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Asia-Pacific Meglitinide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Asia-Pacific Meglitinide Market is expected to register a CAGR greater than 1.5% over the forecast period.

People with Covid-19 had a statistically greater incidence of type 2 diabetes and other kinds of diabetes in the Asia-Pacific region. Individuals with no history of diabetes who recovered from SARS-CoV-2 infections have been reported to develop insulin resistance and reduced insulin secretion. It has been proposed that integrated rather than disease-specific methods are needed for post-Covid syndrome diagnosis and therapy.

Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels. The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

This is driving the demand for Meglitinides in Asia-Pacific, thereby driving the market in focus during the forecast period.​

Key Market TrendsRising Diabetes Prevalence in Asia-Pacific Region

Among the Asia-Pacific countries, Australia and China dominate around 56% of the total Asia-Pacific Insulin Infusion Pump Market. This is mainly due to the high diabetes prevalence in these countries. China records the highest healthcare expenditure in the Asia-pacific region. According to the National Bureau of Statistics of China; MOH (China) in 2020 China’s expenditure on health is Yuan 7,217.5 billion. Expenditure includes government spending, collective spending, and private out-of-pocket spending on health care. In 2020, health expenditure in China equaled about 7.1 percent of the GDP, up from 6.67 percent in the previous year. Health insurance is voluntary in China, but the share of the population being covered by basic health insurance has grown quickly in the last ten years.

In 2021, according to Diabetes Australia, “The Australian health system spends USD 2.5 billion per annum directly on diabetes”. On top of this diabetes is a leading cause of heart disease, which costs the health system more than USD 2 billion per annum, chronic kidney disease which costs USD 1.7 billion, and stroke which costs USD 660 million.

China is Expected to Dominate the Asia-Pacific Meglitinides Market.

This class of drugs, also known as nonsulfonylurea secretagogues, is newer than sulfonylureas (chlorpropamide [brand name Diabinese], glyburide [DiaBeta, Glynase, Micronase], glipizide [Glucotrol], glipizide extended release [Glucotrol XL], and glimepiride [Amaryl]).

Meglitinides, for example, bind to the sulfonylurea receptor in beta cells (pancreatic insulin-producing cells), but at a different site than sulfonylureas. Meglitinides' interaction with the receptor is not as "tight" as that of sulfonylureas, resulting in a much shorter duration of action and a higher blood glucose level required before the drugs produce pancreatic insulin secretion. There are currently two meglitinides available in the United States: repaglinide (Prandin) and nateglinide (Starlix). Both are approved for use in Type 2 diabetes patients, both alone and in combination with other oral diabetes medications. The main effect of meglitinides is to lower after-meal blood glucose levels, which results in a lower HbA1c (an indicator of blood glucose control over the previous 2–3 months).

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The Meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.